CN103167874A - 美昔前列素在炎性肠病和/或肠易激综合症的治疗中的用途 - Google Patents

美昔前列素在炎性肠病和/或肠易激综合症的治疗中的用途 Download PDF

Info

Publication number
CN103167874A
CN103167874A CN2011800502426A CN201180050242A CN103167874A CN 103167874 A CN103167874 A CN 103167874A CN 2011800502426 A CN2011800502426 A CN 2011800502426A CN 201180050242 A CN201180050242 A CN 201180050242A CN 103167874 A CN103167874 A CN 103167874A
Authority
CN
China
Prior art keywords
mexiprostil
compound
ibs
mexiprost
ibd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800502426A
Other languages
English (en)
Chinese (zh)
Inventor
亚历山德罗·阿桑德里
卢吉·摩洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo Technologies Ltd
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Publication of CN103167874A publication Critical patent/CN103167874A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN2011800502426A 2010-10-19 2011-10-18 美昔前列素在炎性肠病和/或肠易激综合症的治疗中的用途 Pending CN103167874A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2010A001908 2010-10-19
ITMI2010A001908A IT1402047B1 (it) 2010-10-19 2010-10-19 Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
PCT/IB2011/054627 WO2012052918A1 (en) 2010-10-19 2011-10-18 Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome

Publications (1)

Publication Number Publication Date
CN103167874A true CN103167874A (zh) 2013-06-19

Family

ID=43738034

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800502426A Pending CN103167874A (zh) 2010-10-19 2011-10-18 美昔前列素在炎性肠病和/或肠易激综合症的治疗中的用途

Country Status (9)

Country Link
US (1) US20130202704A1 (enExample)
EP (1) EP2629778B1 (enExample)
JP (1) JP5885749B2 (enExample)
KR (1) KR20140008306A (enExample)
CN (1) CN103167874A (enExample)
BR (1) BR112013009185A2 (enExample)
CA (1) CA2812891A1 (enExample)
IT (1) IT1402047B1 (enExample)
WO (1) WO2012052918A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
AU2011248587A1 (en) * 2011-11-09 2013-05-23 Cosmo Technologies Ltd Controlled release and taste masking oral pharmaceutical composition
CN108685929A (zh) * 2012-04-23 2018-10-23 苏坎波公司 用于治疗具有腹泻的肠易激综合征的方法
AU2016257911B2 (en) * 2015-05-04 2021-02-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivering therapeutic agents into the colon

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
CN1753680A (zh) * 2002-12-27 2006-03-29 苏坎波公司 用于治疗腹部不适的前列腺素衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3704825A1 (de) * 1987-02-16 1988-08-25 Froelich Juergen Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung
EP0325869B1 (en) * 1988-01-28 1992-11-25 Merrell Dow Pharmaceuticals Inc. Novel processes and intermediates
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
ITMI991316A1 (it) * 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
HK1046244B (zh) * 1999-06-14 2005-06-03 科斯默技术有限公司 控制释放与掩蔽味道的口服药物组合物
DE60001623T2 (de) * 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
AU2003209150A1 (en) * 2002-01-04 2003-07-24 Combinatorx, Incorporated Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
ATE435853T1 (de) * 2004-07-02 2009-07-15 Allergan Inc Prostaglandinanaloga

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
CN1753680A (zh) * 2002-12-27 2006-03-29 苏坎波公司 用于治疗腹部不适的前列腺素衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G.SPINA,等: "MDL-646, A NEW SYNTHETIC El-PROSTAGLANDIN WITH LOCAL PROTECTIVE EFFECTS ON THE GASTRIC MUCOSA", 《PROSTAGLANDINS》, vol. 28, no. 2, 31 August 1984 (1984-08-31), pages 158 - 171, XP023448477, DOI: doi:10.1016/0090-6980(84)90053-4 *

Also Published As

Publication number Publication date
CA2812891A1 (en) 2012-04-26
IT1402047B1 (it) 2013-08-28
KR20140008306A (ko) 2014-01-21
JP5885749B2 (ja) 2016-03-15
ITMI20101908A1 (it) 2012-04-20
US20130202704A1 (en) 2013-08-08
JP2013544795A (ja) 2013-12-19
EP2629778B1 (en) 2016-09-21
EP2629778A1 (en) 2013-08-28
WO2012052918A1 (en) 2012-04-26
BR112013009185A2 (pt) 2016-07-26

Similar Documents

Publication Publication Date Title
CN1235578C (zh) 富马酸微型片剂
CN101636152B (zh) 含有西洛他唑的控释制剂及其制备方法
CN103842330B (zh) 抗炎的取代的环丁烯二酮化合物的胆碱盐
JP2002504112A (ja) 上部胃腸管の安全性を高めるためのフィルムコーティング錠
CN103167874A (zh) 美昔前列素在炎性肠病和/或肠易激综合症的治疗中的用途
CN101969931A (zh) 包含霉酚酸的调节释放药物组合物及其方法
JP2002513418A (ja) 治療活性組成物
CN1320926C (zh) 银杏叶提取物组合物及其制备方法
JP4634713B2 (ja) ヘパリン又はその誘導体の経口的投与のための製薬学的組成物
CN105025888B (zh) 肠溶片
JP2025506890A (ja) 治療用の化合物、製剤、およびそれらの使用
CN102046191A (zh) 含有匍匐大戟的组合物及其制备方法
CN115279346A (zh) 包含屈他维林或其盐的控制释放制剂
HRP20000739A2 (en) sPLA<->2<P> INHIBITOR COMPOUNDS FOR TREATMENT OF DISEASE
CN102973541A (zh) 一种l-瓜氨酸在制备抗胃溃疡药物中的应用
CA2538202C (en) Use of ciclesonide for the treatment of inflammatory bowel diseases
US9308220B2 (en) Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
JP2008533186A (ja) 腸炎治療のためのマクロライド類の使用
WO2023002338A1 (en) Compositions, methods of making and using same for the delivery of ulcerogenic drugs thereof
CN105853419B (zh) 一种用于胃溃疡治疗的药物组合物及其应用
MXPA00010463A (en) Spla2
HK1093507A1 (zh) 拉唑类衍生物及其盐和用途
HK1093507B (en) Prazole compound and its salt, and the use thereof
TW201306843A (zh) 控制美沙拉□釋放之口服醫藥錠劑及其獲得方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130619